REGENXBIO Q1 Earnings: Revenue Miss Overshadows Positive Duchenne Gene Therapy Data
Regenxbio’s DMD gene therapy showed strong results, boosting muscle protein and safety, moving closer to FDA approval.
Regenxbio’s DMD gene therapy showed strong results, boosting muscle protein and safety, moving closer to FDA approval.
Hims & Hers missed earnings, lost money, but grew users and expects stronger future growth with higher revenue guidance.
PTC beat estimates, Sephience sales surged, losses small, outlook raised, and analysts upgraded stock on strong growth momentum.
Sarepta reported strong Q1 2026 earnings, with revenue of $730.8M, but shares fell as Elevidys sales dropped 46% due to label restrictions.
Oscar Health posted record profit, strong growth, and lower costs, showing a major turnaround and fast expansion.
Novavax beat forecasts with $140M revenue, boosted by vaccine tech deals, new partnerships, and strong cash position.